Published in Cell Growth Differ on April 01, 1996
EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol (2004) 3.33
Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med (2007) 1.82
EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest (1997) 1.61
Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst (2011) 1.55
High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One (2010) 1.54
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Clin Cancer Res (2015) 1.52
Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer (2014) 1.43
Promiscuous partnerships in Ewing's sarcoma. Cancer Genet (2011) 1.41
Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. Clin Cancer Res (2010) 1.36
Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. J Clin Pathol (2003) 1.35
Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. Am J Pathol (2000) 1.22
EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma. Cancer Res (2009) 1.17
Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res (2013) 1.11
PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. Oncogene (2001) 1.08
Pathology of Ewing's sarcoma/PNET: Current opinion and emerging concepts. Indian J Orthop (2010) 1.02
Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther (2008) 1.02
Chemotherapy in Ewing's sarcoma. Indian J Orthop (2010) 0.88
Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS One (2012) 0.88
Targeting the p53 Pathway in Ewing Sarcoma. Sarcoma (2010) 0.82
gamma-Glutamyl transpeptidase expression in Ewing's sarcoma cells: up-regulation by interferons. Biochem J (2002) 0.82
Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget (2016) 0.81
Progress in the molecular biology of ewing tumors. Sarcoma (1998) 0.80
Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. Oncogene (2013) 0.80
Transformation induced by Ewing's sarcoma associated EWS/FLI-1 is suppressed by KRAB/FLI-1. Br J Cancer (2003) 0.79
Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma. Sarcoma (2011) 0.78
Molecular approaches to sarcoma therapy. Sarcoma (2002) 0.77
Modeling the initiation of Ewing sarcoma tumorigenesis in differentiating human embryonic stem cells. Oncogene (2015) 0.77
Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA. Cancer (2016) 0.77
Molecular alterations in pediatric sarcomas: potential targets for immunotherapy. Sarcoma (1998) 0.76
Potential molecular targets for Ewing's sarcoma therapy. Indian J Med Paediatr Oncol (2012) 0.75
EWS Knockdown and Taxifolin Treatment Induced Differentiation and Removed DNA Methylation from p53 Promoter to Promote Expression of Puma and Noxa for Apoptosis in Ewing's Sarcoma. J Cancer Ther (2014) 0.75
Proteasomal degradation of the EWS-FLI1 fusion protein is regulated by a single lysine residue. J Biol Chem (2016) 0.75
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature (1998) 7.55
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
Drosophila S6 kinase: a regulator of cell size. Science (1999) 6.76
Phosphorylation and activation of p70s6k by PDK1. Science (1998) 6.53
Mammalian TOR: a homeostatic ATP sensor. Science (2001) 6.41
CARD15 mutations in Blau syndrome. Nat Genet (2001) 5.79
Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J (1997) 5.57
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J (1998) 5.34
Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels. Nature (1983) 5.14
Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J (1992) 5.05
Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci U S A (1992) 4.91
Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem (1992) 4.87
Intracellular trafficking and activation of the furin proprotein convertase: localization to the TGN and recycling from the cell surface. EMBO J (1994) 4.46
The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J (1995) 4.26
Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc Natl Acad Sci U S A (1994) 4.16
Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol (2000) 4.15
Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med (2000) 4.13
Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev (2000) 4.05
Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res (1999) 4.04
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet (1998) 3.91
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 3.89
Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol (1997) 3.83
PACS-1 defines a novel gene family of cytosolic sorting proteins required for trans-Golgi network localization. Cell (1998) 3.79
Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Oncogene (1990) 3.74
Activation of p70/p85 S6 kinase by a pathway independent of p21ras. Nature (1994) 3.67
Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature (2001) 3.65
Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis. Trends Cell Biol (1999) 3.50
X-linked Wiskott-Aldrich syndrome in a girl. N Engl J Med (1998) 3.45
Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer--a meta-analysis. Clin Oncol (R Coll Radiol) (2002) 3.33
Concurrent Langerhans cell histiocytosis and myelodysplasia in children. Med Pediatr Oncol (2000) 3.24
New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci U S A (1998) 3.14
4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. Proc Natl Acad Sci U S A (1996) 3.09
Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6. Science (2000) 3.07
Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A (1993) 3.07
Human fur gene encodes a yeast KEX2-like endoprotease that cleaves pro-beta-NGF in vivo. J Cell Biol (1990) 3.03
HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nat Cell Biol (2000) 2.95
p70s6k function is essential for G1 progression. Nature (1993) 2.91
Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst (2000) 2.87
The modular phosphorylation and activation of p70s6k. FEBS Lett (1997) 2.85
beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature (1996) 2.82
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia (2009) 2.78
Endometrial carcinoma--relative effectiveness of adjuvant irradiation vs therapy reserved for relapse. Gynecol Oncol (1996) 2.78
BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res (1997) 2.77
Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology (2001) 2.73
Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med (1990) 2.73
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev (2000) 2.72
EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet (1993) 2.72
The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k. Mol Cell Biol (1997) 2.66
The effect of serum, EGF, PGF2 alpha and insulin on S6 phosphorylation and the initiation of protein and DNA synthesis. Cell (1982) 2.63
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer (2005) 2.62
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene (2000) 2.61
HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol (1997) 2.59
Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood (1999) 2.48
Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev (1999) 2.48
Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant. J Biol Chem (1993) 2.40
Substrate recognition determinants of the mitogen-activated 70K S6 kinase from rat liver. J Biol Chem (1992) 2.38
Antibiotic treatment in preterm premature rupture of membranes and neonatal morbidity: a metaanalysis. Am J Obstet Gynecol (1996) 2.36
Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet (1999) 2.35
Effect of adenotonsillectomy on nocturnal hypoxaemia, sleep disturbance, and symptoms in snoring children. Lancet (1990) 2.33
Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients. Cell (1993) 2.31
Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer (1992) 2.31
MAP2 kinase and 70K S6 kinase lie on distinct signalling pathways. Nature (1991) 2.30
Genetic analyses of chromosome 12 loci in Crohn's disease. Gut (2000) 2.30
Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet (1994) 2.28
alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc Natl Acad Sci U S A (1998) 2.28
The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol Cell Biol (1996) 2.28
Explained variation for logistic regression. Stat Med (1996) 2.27
PACS-1 binding to adaptors is required for acidic cluster motif-mediated protein traffic. EMBO J (2001) 2.26
Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol (1999) 2.25
Intracellular trafficking of furin is modulated by the phosphorylation state of a casein kinase II site in its cytoplasmic tail. EMBO J (1995) 2.22
A solution to the problem of monotone likelihood in Cox regression. Biometrics (2001) 2.22
Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood (2000) 2.21
Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia (2000) 2.21
Structure of a family of rat amylase genes. Nature (1980) 2.19
Association of p53 mutations with short survival in colorectal cancer. Gastroenterology (1994) 2.19
DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol Cell Biol (1994) 2.18
Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol (2001) 2.15
Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet (1995) 2.13
Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer (1988) 2.11
BMP-4 is proteolytically activated by furin and/or PC6 during vertebrate embryonic development. EMBO J (1998) 2.11
Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer (1998) 2.09
Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res (1990) 2.09
Cloning of the mitogen-activated S6 kinase from rat liver reveals an enzyme of the second messenger subfamily. Proc Natl Acad Sci U S A (1990) 2.09
Multiple phosphorylation of ribosomal protein S6 during transition of quiescent 3T3 cells into early G1, and cellular compartmentalization of the phosphate donor. Proc Natl Acad Sci U S A (1979) 2.09
Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset of sites. J Biol Chem (1995) 2.08
Nuclear localization of p85s6k: functional requirement for entry into S phase. EMBO J (1994) 2.06
Identification and characterization of a mitogen-activated S6 kinase. Proc Natl Acad Sci U S A (1988) 2.06
Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N Engl J Med (1996) 2.05
Survival and acquired genetic alterations in colorectal cancer. Gastroenterology (1992) 2.02
Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol (2001) 2.01